Tolerability and outcomes of neuroendocrine tumors treated with peptide receptor radionuclide therapy and stereotactic body radiation therapy

#4257

Introduction: The addition of stereotactic body radiation therapy (SBRT) to patients treated with PRRT may provide synergistic benefit by targeting specific sites of disease that represent areas of tumor heterogeneity. Little is known regarding the efficacy or potential toxicity of this approach. A retrospective review of patients with NEN treated with sequential PRRT and SBRT was performed to provide preliminary outcome and toxicity data to inform further combined treatment strategies.

Aim(s): To determine the safety profile and clinical outcomes of patients with metastatic neuroendocrine tumors treated with sequential PRRT and SBRT.

Materials and methods: Retrospective review performed of 21 patients treated with both SBRT (64 individual targets) and PRRT. Patient data were abstracted from the clinical and radiation planning records. Toxicity was evaluated using CTCAE v5.0. RECIST v1.1 or SPINO criteria were utilised to evaluate treatment response. Kaplan-Meier method utilised to estimate survival, and the log-rank test to compare survival rates between groups. Start date of follow-up is the date of completion of the last of any recorded treatment (either SBRT or PRRT) to avoid immortal time bias.

Conference:

Presenting Author: Myrehaug S

Authors: Nunez Rodriguez J, Ng S, Chen H, Singh S, Hallet J,

Keywords: PRRT, Radiation, SABR, SBRT,